1,981 results match your criteria: "the Ohio State University Medical Center[Affiliation]"
medRxiv
March 2022
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Front Oncol
February 2022
Department of Radiation Oncology at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States.
Background: Chest radiation therapy (RT) has been associated with increased cardiac morbidity and mortality in numerous studies including the landmark Darby study published in 2013 demonstrating a linear increase in cardiac mortality with increasing mean heart radiation dose. However, the extent to which cardiotoxicity has been incorporated as an endpoint in prospective RT studies remains unknown.
Methods: We queried clincaltrials.
Plast Reconstr Surg Glob Open
January 2022
Department of Plastic and Reconstructive Surgery, The Ohio State University Medical Center, Columbus, Ohio.
Unlabelled: The early career academic plastic surgeon strives to be an expert surgeon, an innovative researcher, and an impactful educator. Navigating these challenges is difficult in a healthcare landscape with diminishing public research funding, increasing demand from institutions for clinical productivity, and decreased value of surgical education. To help the junior academic plastic surgeon, this article discusses the fundamental aspects of developing an early academic plastic surgery practice, rooted in clinical care, research, and education.
View Article and Find Full Text PDFAm J Dermatopathol
March 2022
Director of Dermatopathology, Divisions of Dermatopathology and Hematopathology, University of Virginia, Charlottesville, VA.
The distinction of metastatic carcinomas to the skin (MCS) from cutaneous adnexal carcinomas can pose a significant diagnostic challenge. The differentiation between (MCS) from a primary cutaneous adnexal tumor is one of the most difficult tasks in the field of dermatopathology, and immunohistochemistry has only been partially helpful in solving this problem. In routine diagnostic surgical pathology, it is essential to identify the myoepithelial cell layer by immunohistochemistry to distinguish between an in situ and invasive breast carcinomas and when establishing the presence of microinvasion.
View Article and Find Full Text PDFJ Clin Med
January 2022
Division of Medical Oncology Yale Cancer Center, New Haven, CT 06520, USA.
(1) Background: The objective of this study was to determine the long-term efficacy of fractional CO laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatments of fractional CO laser therapy and returned for a 4 week follow-up.
View Article and Find Full Text PDFLeukemia
May 2022
Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
Clin Gastroenterol Hepatol
July 2022
Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Medical Center, Columbus, Ohio.
J Cardiovasc Electrophysiol
April 2022
Sparrow Clinical Research Institute, Lansing, Michigan, USA.
Background: Insertable cardiac monitors (ICMs) are essential for ambulatory arrhythmia diagnosis. However, definitive diagnoses still require time-consuming, manual adjudication of electrograms (EGMs).
Objective: To evaluate the clinical impact of selecting only key EGMs for review.
Postgrad Med J
February 2022
Comprehensive Transplant Center, Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Eur Heart J
March 2022
Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.
Gynecol Oncol
March 2022
Women's College Research Institute, Women's College Hospital, 76 Grenville St., Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address:
Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g.
View Article and Find Full Text PDFObstet Gynecol
February 2022
Palo Alto Medical Foundation/California Pacific/Sutter Research Institute, Palo Alto, California; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York; Penn State Hershey Medical Center, Hershey, Pennsylvania; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, Arizona; Stanford University School of Medicine, Stanford, California; Duke University, Durham, North Carolina; Indiana University, Indianapolis, Indiana; The Ohio State University Medical Center, Columbus Ohio; Oklahoma University Hospital, Stephenson Cancer Center, Oklahoma City, Oklahoma; Moffitt Cancer Center, Tampa, Florida; Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland; Women's Cancer Center of Nevada, Las Vegas, Nevada; University of California at Irvine, Irvine, California; and Riverside Methodist Hospital, Columbus, Ohio.
Objective: To assess the presentation, characteristics, and prognostic significance of symptoms in patients with high-risk early-stage epithelial ovarian cancer.
Methods: A retrospective chart review was performed on all patients enrolled in a phase III clinical trial (GOG 157). All patients had surgically staged, high-risk early-stage epithelial ovarian cancer (stage IA-IB and grade 3, any clear cell, stage IC or II).
JACC CardioOncol
December 2021
Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio, USA.
Clin Transplant
April 2022
Divison of Cardiac Surgery, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.
The worldwide pandemic caused by COVID-19, resulting from the infection by betacoronarvirus SARS-CoV-2, has dramatically altered healthcare worldwide. Due to the highly contagious nature of SARS-CoV2, coupled with hospitals and intensive care units being overwhelmed, numerous transplant programs either slowed or shut down completely. While there have been isolated reports of COVID-19 in transplant recipients, no study to date has examined how COVID-19 affected actual transplant patterns and outcomes in the United States.
View Article and Find Full Text PDFFront Surg
December 2021
Department of Anesthesiology, The Ohio State University Medical Center, Columbus, OH, United States.
Recently formed ileostomies may produce an average of 1,200 ml of watery stool per day, while an established ileostomy output varies between 600-800 ml per day. The reported incidence of renal impartment in patients with ileostomy is 8-20%, which could be caused by dehydration (up to 50%) or high output stoma (up to 40%). There is a lack of evidence if an ileostomy could influence perioperative fluid management and/or surgical outcomes.
View Article and Find Full Text PDFJ Cardiothorac Vasc Anesth
August 2022
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:
Kidney Int Rep
December 2021
Division of Nephrology, The Ohio State University Medical Center, Columbus, Ohio, USA.
Clin Genet
March 2022
Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Approximately 1% of the Ashkenazi Jewish population carries the BRCA2 6174delT (c.5946del) pathogenic variant. It is important to have accurate knowledge of the risks of breast and ovarian cancer associated with this specific variant so that women may be counseled accordingly.
View Article and Find Full Text PDFGenes Chromosomes Cancer
April 2022
Department of Pathology and Laboratory Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Cutaneous fibromyxoid neoplasms (CFMN) comprise a vast category of benign and malignant tumors that include, but are not limited to, low-grade fibromyxoid sarcoma, myxofibrosarcoma, myxoid dermatofibrosarcoma protuberans, myxoid solitary fibrous tumor, and myxoid neurofibroma with differing implications for treatment and prognosis. Herein, a case of CFMN arising as a painless, slow-growing, flesh-colored forearm mass in a 53-year-old female is presented. The neoplasm comprised of copious myxoid material with banal spindle cells, exhibiting mild hyperchromasia, dissecting the dermal collagen table.
View Article and Find Full Text PDFJ Interv Card Electrophysiol
April 2022
Sparrow Clinical Research Institute, Lansing, MI, USA.
Purpose: SharpSense™ technology is an upgradable software enhancement introduced to the Abbott Confirm Rx™ insertable cardiac monitor (ICM). This study aims to characterize the real-world performance of SharpSense algorithms by comparing device detected pause and bradycardia episodes before and after the SharpSense upgrade.
Methods: Confirm Rx devices with at least 90 days monitoring each before and after SharpSense upgrade were included in the study.
Transl Oncol
January 2022
Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, 1800 Canon Drive, 1300G, Columbus, OH 43210, United States; Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, The Ohio State University Medical Center, Columbus, OH 43210, United States. Electronic address:
Tumor treating fields (TTFields)-an intermediate-frequency, electric field therapy-has emerged as a promising alternative therapy for the treatment of solid cancers. Since the first publication describing the anticancer effects of TTFields in 2004 there have been numerous follow-up studies by other groups, either to confirm the efficacy of TTFields or to study the primary mechanism of interaction. The overwhelming conclusion from these in vitro studies is that TTFields reduce the viability of aggressively replicating cell lines.
View Article and Find Full Text PDFNeurol Clin Pract
October 2021
Minnesota Epilepsy Group (PEP), Saint Paul; Department of Neurology (JMS), University of California at Los Angeles; Penn Epilepsy Center (DAB), Hospital of the University of Pennsylvania, Philadelphia; Department of Neurology (LL), The Ohio State University Medical Center, Columbus; Human Care Systems Inc. (NS), San Francisco, CA; MedVal Scientific Information Services (LM), Princeton, NJ; and Health Division (EYP), Kantar Health, New York, NY.
Objective: To explore the perspectives of adult patients with epilepsy, caregivers, and health care professionals (HCPs) on treatment for seizures and treatment decisions, we developed and administered the STEP Survey (Seize the Truth of Epilepsy Perceptions).
Methods: Participants were recruited from online panel M3 and by Rare Patient Voice and completed the self-administered online STEP Survey. Analysis of variance and chi-square tests were used for group comparisons.
Mol Cancer Res
March 2022
Department of Radiation Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California.
Unlabelled: Lung squamous cell carcinoma (LUSC) accounts for one of three of non-small cell lung carcinoma (NSCLC) and 30% of LUSC patients present with locally advanced, unresectable/medically inoperable disease, who are commonly treated with definitive chemoradiation. However, disease relapse in the radiation fields occurs in one of three cases. We aim to explore the underlying molecular mechanisms of chemoradiation resistance of LUSC.
View Article and Find Full Text PDFEur Heart J
January 2022
Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, 452 W. 10th Ave. Columbus, OH 43210, USA.
Aims: The national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in breast cancer patients are unknown.
Methods And Results: Using the Surveillance, Epidemiology, and End Results-Medicare-linked database, we identified females, ≥66 years old, with a new primary diagnosis of breast cancer from 2007 through 2014. These patients were individually matched 1:1 to Medicare enrolees without cancer, and each pair was followed for 1 year to identify a primary outcome of AF.
Gynecol Oncol Rep
November 2021
Division of Gynecologic Oncology, Obstetrics, Gynecology, Women's Health Institute, Cleveland Clinic, Desk A81, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
Objectives: To investigate the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of iterval debulking surgery (IDS) in women with advanced uterine serous carcinoma (USC) following neoadjuvant chemotherapy (NACT).
Methods: An IRB-approved single-institution prospective registry was queried to identify women with incidentally identified USC at the time of IDS + HIPEC for high-grade serous carcinoma. Patient demographic, oncologic, and surgical outcomes data were recorded.